Publication: The Use of SGLT2i and GLP-1 RA in patients with type 2 diabetes in thailand: Evidence review and recommendations
2
Issued Date
2021-11-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-85120625176
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.104, No.11 (2021), 1850-1865
Suggested Citation
Rungroj Krittayaphong, Bancha Satirapoj, Boonsong Ongphiphadhanakul, Kriengsak Vareesangthip, Sompongse Suwanwalaikorn, Wacin Buddhari The Use of SGLT2i and GLP-1 RA in patients with type 2 diabetes in thailand: Evidence review and recommendations. Journal of the Medical Association of Thailand. Vol.104, No.11 (2021), 1850-1865. doi:10.35755/jmedassocthai.2021.11.13163 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77696
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The Use of SGLT2i and GLP-1 RA in patients with type 2 diabetes in thailand: Evidence review and recommendations
Abstract
Background: Cardiovascular (CV) and renal comorbidities are common among type 2 diabetes (T2D) patients, and significantly increase the cost and burden of care. Both sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve key outcomes including major CV events, hospitalization for heart failure, and renal outcomes, albeit to varying degrees in different T2D populations. Materials and Methods: The authors reviewed evidence from GLP-1 RA and SGLT2i CV outcomes trials and real-world studies in Thailand and elsewhere. Results: The authors formulated recommendations to guide selection of anti-diabetes medication based on patients clinical characteristics and CV or renal risk profile. Conclusion: These recommendations could help guide management of CV/renal comorbidities and risk alongside glucose-lowering therapy for individual patients.